DELpro: A New Method of Hit Discovery
DNA-Encoded Library (DEL) technology involves a novel affinity selection process that integrates chemistry, biology, bioinformatics and computational chemistry to facilitate a rapid drug discovery process, allowing access to more chemical space with lower cost.
In contrast to high throughput screening, DEL requires a very small amount of target protein and minimum assay development. More importantly, it disrupts the concept of “cost-per-well” and allows testing billions of compounds in one tube.
DELpro provides a one-stop solution from target to hit series. Our extended platform enables overall planning and management of protein production, DEL library production, affinity selection, data analysis, hit validation and structural biology for further optimization.
- DRUG DISCOVERY AND INNOVATION
- TECHNOLOGY PLATFORMS
- Cells and Protein Science
- Chemical Biology and Proteomics
- Clinical Bioanalysis
- Gene Manipulation
- in silico services
- in vitro biology
- in vivo Pharmacology
- in vivo Toxicology
- Screening Services
- Structural Biology
- THERAPEUTIC AREAS
- THERAPEUTIC MODALITIES